James Davis, Biotechnology Consultant, Elected Chair of The Leukemia & Lymphoma Society's National Board of Directors

WHITE PLAINS, N.Y., July 16, 2014 /PRNewswire-USNewswire/ -- James Davis, Ph.D., JD, a consultant in crisis management and the launch of new technologies for biotechnology and other companies, has been elected chairman of the national board of directors of The Leukemia & Lymphoma Society (LLS), effective July 1. LLS is the world's largest voluntary health agency dedicated to finding cures and ensuring access to treatments for patients with blood cancers.

Davis is the former executive vice president, general counsel and secretary of Human Genome Sciences, Inc., a biopharmaceutical company that pioneered new treatments in the areas of auto-immune diseases, cancer, and bioterrorism. His professional background has focused on the intersection of science, business, and law, particularly in issues related to the commercialization of new technologies.

Davis, who will serve a two year term as chair, is a chronic myeloid leukemia (CML) patient and clinical trial participant. He has served in several capacities with LLS, starting in 2007, including vice-chair of the board of directors, chair of the mission oversight committee, and as a member of the Therapy Acceleration Program (TAP) medical & scientific affairs and executive committees. Davis has also served for two years as the co-chair of the National Capital Area chapter's annual Leukemia Ball, helping to raise approximately $6 million.

"It's an honor to be elected to this position by my colleagues on the board," said Davis. "I look forward to working with the board to help advance the LLS mission."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

Contact:
Andrea Greif
Tel: (914) 821-8958
Cell: (914) 772-3027
[email protected]

SOURCE The Leukemia & Lymphoma Society